申请人:Kinoyama Isao
公开号:US20120041036A1
公开(公告)日:2012-02-16
An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT
5A
receptor modulating action.
It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT
5A
receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.
本发明的目的是提供一种基于血清素5-HT5A受体调节作用的用于治疗或预防痴呆症、精神分裂症的优良药剂。发现酰基胍衍生物,其中胍基通过一个羰基与萘的一个环相结合,另一个环上结合有一个环状基团,表现出强效的5-HT5A受体调节作用和基于该作用的优良药理作用。本发明可用作治疗或预防痴呆症、精神分裂症、躁郁症或注意力缺陷多动障碍的优良药剂。